Edgewise Therapeutics Stock Analysis
| EWTX Stock | USD 22.80 0.57 2.44% |
Edgewise Therapeutics is undervalued with Real Value of 29.24 and Target Price of 49.43. The main objective of Edgewise Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Edgewise Therapeutics is worth, separate from its market price. There are two main types of Edgewise Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Edgewise Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Edgewise Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Edgewise Stock trading window is adjusted to America/New York timezone.
Edgewise |
Edgewise Stock Analysis Notes
About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Edgewise Therapeutics was currently reported as 4.84. The company recorded a loss per share of 1.45. Edgewise Therapeutics had not issued any dividends in recent years. Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. Edgewise Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 42 people. To learn more about Edgewise Therapeutics call Kevin Koch at 720 262 7002 or check out https://www.edgewisetx.com.Edgewise Therapeutics Investment Alerts
| Edgewise Therapeutics generated a negative expected return over the last 90 days | |
| Edgewise Therapeutics has high historical volatility and very poor performance | |
| Edgewise Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (133.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Edgewise Therapeutics currently holds about 248.4 M in cash with (109.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.99. | |
| Edgewise Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Intech Investment Management LLC Buys 14,944 Shares of Edgewise Therapeutics, Inc. - MarketBeat |
Edgewise Therapeutics Upcoming and Recent Events
Earnings reports are used by Edgewise Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Edgewise Largest EPS Surprises
Earnings surprises can significantly impact Edgewise Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-09 | 2021-06-30 | -0.18 | -0.21 | -0.03 | 16 | ||
2021-11-10 | 2021-09-30 | -0.22 | -0.26 | -0.04 | 18 | ||
2024-05-09 | 2024-03-31 | -0.39 | -0.33 | 0.06 | 15 |
Edgewise Therapeutics Environmental, Social, and Governance (ESG) Scores
Edgewise Therapeutics' ESG score is a quantitative measure that evaluates Edgewise Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Edgewise Therapeutics' operations that may have significant financial implications and affect Edgewise Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Edgewise Stock Institutional Investors
| Shares | Deerfield Management Co | 2024-12-31 | 2.1 M | State Street Corp | 2024-12-31 | 1.7 M | Geode Capital Management, Llc | 2024-12-31 | 1.6 M | Driehaus Capital Management Llc | 2024-12-31 | 1.5 M | Bellevue Group Ag | 2024-12-31 | 1.4 M | Viking Global Investors Lp | 2024-12-31 | 1.2 M | Mpm Oncology Impact Management Lp | 2024-12-31 | 1.1 M | Artisan Partners Limited Partnership | 2024-12-31 | 1.1 M | New Leaf Venture Partners, L.l.c. | 2024-12-31 | 1 M | Orbimed Advisors, Llc | 2024-12-31 | 15 M | Ra Capital Management, Llc | 2024-12-31 | 8.9 M |
Edgewise Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.22 B.Edgewise Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | (0.29) | (0.28) |
Management Efficiency
Edgewise Therapeutics has return on total asset (ROA) of (0.2401) % which means that it has lost $0.2401 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.344) %, meaning that it created substantial loss on money invested by shareholders. Edgewise Therapeutics' management efficiency ratios could be used to measure how well Edgewise Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.29 in 2025. Return On Capital Employed is likely to drop to -0.36 in 2025. At this time, Edgewise Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 5.7 M in 2025, whereas Total Assets are likely to drop slightly above 299.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.97 | 2.79 | |
| Tangible Book Value Per Share | 4.97 | 2.79 | |
| Enterprise Value Over EBITDA | (15.30) | (16.07) | |
| Price Book Value Ratio | 5.37 | 5.64 | |
| Enterprise Value Multiple | (15.30) | (16.07) | |
| Price Fair Value | 5.37 | 5.64 | |
| Enterprise Value | 2.2 B | 2.3 B |
Understanding the operational decisions made by Edgewise Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 25th of March, Edgewise Therapeutics shows the Variance of 13.05, mean deviation of 2.65, and Standard Deviation of 3.61. Edgewise Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Edgewise Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Edgewise Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Edgewise Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Edgewise Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edgewise Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edgewise Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Edgewise Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edgewise Therapeutics Outstanding Bonds
Edgewise Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Edgewise Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Edgewise bonds can be classified according to their maturity, which is the date when Edgewise Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US28035QAB86 Corp BondUS28035QAB86 | View | |
| Edgewell 55 percent Corp BondUS28035QAA04 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Edgewise Therapeutics Predictive Daily Indicators
Edgewise Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Edgewise Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Edgewise Therapeutics Corporate Filings
F4 | 11th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 21st of February 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 7th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of February 2025 Other Reports | ViewVerify | |
F4 | 30th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 23rd of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Edgewise Therapeutics Forecast Models
Edgewise Therapeutics' time-series forecasting models are one of many Edgewise Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Edgewise Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Edgewise Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Edgewise Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Edgewise shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Edgewise Therapeutics. By using and applying Edgewise Stock analysis, traders can create a robust methodology for identifying Edgewise entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Edgewise Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Edgewise analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Edgewise analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 49.43 | Strong Buy | 7 | Odds |
Most Edgewise analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Edgewise stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Edgewise Therapeutics, talking to its executives and customers, or listening to Edgewise conference calls.
Edgewise Stock Analysis Indicators
Edgewise Therapeutics stock analysis indicators help investors evaluate how Edgewise Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Edgewise Therapeutics shares will generate the highest return on investment. By understating and applying Edgewise Therapeutics stock analysis, traders can identify Edgewise Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 86.1 M | |
| Total Stockholder Equity | 459.2 M | |
| Capital Lease Obligations | 4.7 M | |
| Property Plant And Equipment Net | 11.1 M | |
| Cash And Short Term Investments | 470.2 M | |
| Net Invested Capital | 459.2 M | |
| Shares Float | 54.4 M | |
| Cash | 41.7 M | |
| 200 Day M A | 25.3324 | |
| 50 Day M A | 26.5628 | |
| Net Interest Income | 25 M | |
| Total Current Liabilities | 23.9 M | |
| Investments | -184.7 M | |
| Stock Based Compensation | 24.7 M | |
| Common Stock Shares Outstanding | 92.4 M | |
| Free Cash Flow | -110.3 M | |
| Operating Income | -158.8 M | |
| Other Current Assets | 5.3 M | |
| Accounts Payable | 5.6 M | |
| Net Debt | -36.9 M | |
| Depreciation | 2.3 M | |
| Non Current Assets Total | 11.3 M | |
| Liabilities And Stockholders Equity | 486.8 M | |
| Non Currrent Assets Other | 262 K |
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.